Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReT01 ACT in Advanced Solid Tumors
NCT06257680Phase 1Recruiting
- Sponsor
- Beijing Xunsheng Biomedical Research
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ReT01 ACT in solid tumor (advanced stage), sponsored by Beijing Xunsheng Biomedical Research. Primary endpoints: Maximal Tolerance Dose at Day 28, Dose Limiting Toxicity at Day 28 and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
ReT01 ACT
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06257680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06257680.